Post by FamiCord Group

And that's not all that happened at #EACD2026 in the field of cellular therapies. During the poster session, Michał Bielak, MD, presented the first data from a medical therapeutic experiment using an MSC-based ATMP product for children with cerebral palsy, manufactured by the FamiCord Manufacturing Facility in Warsaw. The preliminary results are encouraging. Importantly, no treatment-related adverse events have been observed to date, supporting the favorable safety profile of the therapy. While further research and longer-term observations are needed, these early findings represent another important step in exploring the potential of advanced cellular therapies for patients with cerebral palsy. We are proud to see innovative research based on FamiCord-developed ATMP products being presented at leading international scientific meetings and contributing to the growing body of knowledge in regenerative medicine. Congratulations to Dr. Michał Bielak and all collaborators involved in this important project. #FamiCordGroup #EACD2026 #CerebralPalsy #MSC #ATMP #CellTherapy #StemCells